Physician profile
Thomas K Sleweon
NPI 1114909769
$6,475.32
in general payments reported to CMS, 2019-2025
27 companies · $1,544 in 2025
The $1,544 reported for 2025 was more than what 83% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $385 · 2021: $484 · 2022: $907 · 2023: $1,092 · 2024: $1,322 · 2025: $1,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,882 · Education: $76.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,881.79 |
| Education | $76.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,312.76 | 2019-2025 | Dovato, Cabenuva |
| Abbvie INC. | $948.88 | 2019-2025 | Teflaro, Dalvance |
| Merck Sharp & Dohme LLC | $615.72 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Paratek Pharmaceuticals, INC. | $605.51 | 2020-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $480.46 | 2020-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Gilead Sciences, INC. | $353.68 | 2019-2025 | Veklury |
| Shionogi INC | $332.54 | 2022-2025 | Fetroja |
| Ferring Pharmaceuticals INC. | $261.85 | 2023-2025 | Rebyota |
| Cumberland Pharmaceuticals, INC. | $232.59 | 2019-2024 | Vibativ |
| Napo Pharmaceuticals INC | $219.61 | 2019-2024 | Mytesi |
| Smith+Nephew, INC. | $218.74 | 2019-2025 | Collagenase Santyl |
| La Jolla Pharmaceutical Company | $141.10 | 2020-2023 | Xerava |
| Theratechnologies INC. | $139.21 | 2019-2025 | Egrifta, Trogarzo |
| Insmed, INC. | $124.61 | 2019-2020 | |
| Janssen Biotech, INC. | $101.11 | 2019-2023 | Symtuza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyera Pharmaceuticals, LLC | $71.21 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $46.28 | 2025 | Vowst |
| Mayne Pharma Commercial LLC | $41.54 | 2020 | |
| Emd Serono, INC. | $38.11 | 2024-2025 | |
| Philips North America LLC | $34.54 | 2019-2025 | Vest Therapy Und |
| Vanda Pharmaceuticals INC. | $31.17 | 2021 | |
| Allergan, INC. | $30.43 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $25.56 | 2019-2020 | |
| Octapharma USA, INC. | $20.05 | 2025 | Panzyga |
| Convatec INC. | $18.73 | 2019 | |
| Romark Laboratories, Lc | $16.55 | 2020 | |
| Dynavax Technologies Corporation | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sleweon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.